North America Injectable Drug Delivery Market – by Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics [Diabetes & Oncology] – Forecasts to 2017
The North American injectable drug delivery technologies market was valued at $9.3 billion in 2012; it is expected to reach $16.6 billion by 2017 at a CAGR of 12.3% from 2012 to 2017. Injectable drug delivery technologies are the combination of two major segments; devices and formulations. The North American injectable drug delivery formulations technologies market was the largest segment in this market. In addition, the market is segmented on the basis of its therapeutic applications. In therapeutic area, hormonal disorders command the major segment of injectable drug delivery technologies market due to high demand of injectable in treatment of diabetes. However, auto-immune diseases are the fastest growing segment of this market due to the advent of biologics (tumor necrosis factor (TNF) and Interleukin 1 (IL-1)) and improving patient compliance by the development of self injection devices.
The major markets covered in this report are United States and Canada. The United States accounted for the largest market of the North American injectable drug delivery technologies market in the year 2012. However, Canada is expected to witness high growth due to growing prevalence of diabetes and autoimmune diseases such as multiple sclerosis and rheumatoid arthritis, increase in approval of injectable formulation and device, favorable reimbursement and rise in injectable cosmetic treatments.
The growth of the injectable drug delivery technologies market is driven by factors such as innovations in injectable drug delivery devices, rising prevalence of diabetes in the U.S. and Canada, improving patient compliance and rise in partnerships, collaborations and acquisitions among prominent players in this market. However, factors such as product recalls, regulatory hurdles for approval of new device sand formulations and needle-stick injuries and infections, are restraining the growth of the market.
Scope of the Report
This research report categorizes and analyzes the North American injectable drug delivery technologies market under two broad segments - devices and formulations. Both of these markets are broken down into segments and sub-segments, providing exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Furthermore, due to wide range of applications of injectable drug delivery technologies in varied therapeutic areas, the market is segmented into five categories, namely; auto immune diseases, hormonal imbalances, oncology, orphan/rare diseases (Hemophilia, Ribose-5-phosphate isomerase deficiency (RPI deficiency), Cystic Fibrosis, Wilson’s Disease) and others (pain management, allergies, hepatitis C, and aesthetic treatment). Each market is comprehensively analyzed at a granular level by country (United States and Canada) to provide in-depth information on the North American scenario.
Injectable Drug Delivery Technologies Market, By Segment
The major markets covered in this report are United States and Canada. The United States accounted for the largest market of the North American injectable drug delivery technologies market in the year 2012. However, Canada is expected to witness high growth due to growing prevalence of diabetes and autoimmune diseases such as multiple sclerosis and rheumatoid arthritis, increase in approval of injectable formulation and device, favorable reimbursement and rise in injectable cosmetic treatments.
The growth of the injectable drug delivery technologies market is driven by factors such as innovations in injectable drug delivery devices, rising prevalence of diabetes in the U.S. and Canada, improving patient compliance and rise in partnerships, collaborations and acquisitions among prominent players in this market. However, factors such as product recalls, regulatory hurdles for approval of new device sand formulations and needle-stick injuries and infections, are restraining the growth of the market.
Scope of the Report
This research report categorizes and analyzes the North American injectable drug delivery technologies market under two broad segments - devices and formulations. Both of these markets are broken down into segments and sub-segments, providing exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Furthermore, due to wide range of applications of injectable drug delivery technologies in varied therapeutic areas, the market is segmented into five categories, namely; auto immune diseases, hormonal imbalances, oncology, orphan/rare diseases (Hemophilia, Ribose-5-phosphate isomerase deficiency (RPI deficiency), Cystic Fibrosis, Wilson’s Disease) and others (pain management, allergies, hepatitis C, and aesthetic treatment). Each market is comprehensively analyzed at a granular level by country (United States and Canada) to provide in-depth information on the North American scenario.
Injectable Drug Delivery Technologies Market, By Segment
- Injectable Drug Delivery Devices Technologies
- Injectable Drug Delivery Formulations Technologies
- Conventional Injection Devices
- By Materials
- Glass
- Plastics
- By Product
- Fillable Syringes
- Prefilled Syringes
- By Usability
- Reusable
- Disposable
- Self-Injection Devices
- Needle Free Injectors
- By Product
- Fillable Syringes
- Prefilled Syringes
- By Technology
- Jet-based Needle Free Injectors
- Spring-based Needle Free Injectors
- Laser Powered Needle Free Injectors
- Others
- By Usability
- Reusable
- Disposable
- Auto Injectors
- By Product
- Fillable Syringes
- Prefilled Syringes
- By Technology
- Manual Injection Auto Injectors
- Automated Injection Auto Injectors
- By Design
- Standardized Auto Injectors
- Customized Auto Injectors
- By Usability
- Reusable
- Disposable
- Pen Injectors
- By Product
- Single Chambered Pen Injectors
- Dual Chambered Pen Injectors
- By design
- Standardized pen injectors
- Customized pen injectors
- By usability
- Reusable
- Disposable
- Others (blunt needle, micro needle, and nano needle injections)
- Conventional Drug Delivery Formulation
- Solution
- Reconstituted / Lyophilized Formulation
- Novel Drug Delivery Formulation
- Liposomal Systems
- Microspheres
- Nanoparticles
- Polymeric Micelles
- Others (dendrimers, nanosponge, and nanoemulsions)
- Auto Immune Diseases
- Multiple Sclerosis
- Rheumatoid Arthritis
- Crohn's Diseases
- Psoriasis
- Others
- Hormonal Disorders
- Diabetes
- Antithrombotic/Thrombolytic Therapy
- Reproductive Health Diseases
- Anemia
- Osteoporosis
- Others
- Orphan Diseases
- Oncology
- Others
- Pain Management
- Allergies
- Hepatitis C
- Aesthetic Treatment
1 INTRODUCTION
1.1 KEY TAKE-AWAYS
1.2 REPORT DESCRIPTION
1.3 MARKETS COVERED
1.4 STAKEHOLDERS
1.5 RESEARCH METHODOLOGY
1.5.1 MARKET SIZE
1.5.2 MARKET SHARE
1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES
1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES
1.5.5 ASSUMPTIONS
2 EXECUTIVE SUMMARY
3 MARKET OVERVIEW
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 MARKET DYNAMICS
3.4 DRIVERS
3.4.1 INNOVATIONS IN INJECTABLE DRUG DELIVERY DEVICES
3.4.2 SURGE OF BIOLOGICS
3.4.3 RISING PREVALENCE OF DIABETES IN THE U.S. AND CANADA
3.4.4 IMPROVEMENT IN PATIENT COMPLIANCE
3.4.5 INCESSANT RISE IN PARTNERSHIPS, COLLABORATIONS AND ACQUISITIONS
3.5 RESTRAINTS
3.5.1 PRODUCT RECALLS
3.5.2 STRINGENT REGULATORY SYSTEMS
3.5.3 NEEDLE-STICK INJURIES AND INFECTIONS
3.6 OPPORTUNITIES
3.6.1 DEVELOPMENT OF BIOSIMILARS
3.6.2 ADVANCEMENTS IN NANOTECHNOLOGY
AND OTHERS
3.7 CHALLENGES
3.7.1 SUSTAINABILITY OF PLAYERS IN HIGHLY COMPETITIVE MARKET
3.8 MARKET SHARE ANALYSIS, BY MAJOR PLAYERS
3.8.1 INJECTABLE DRUG DELIVERY DEVICES
4 INJECTABLE DRUG DELIVERY DEVICES TECHNOLOGIES MARKET
4.1 INTRODUCTION
4.2 MARKET SEGMENTATION
4.3 MANUFACTURERS CRITERIA FOR SELECTION OF AN INJECTABLE DEVICE
4.4 CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES
4.4.1 BY USABILITY
4.4.1.1 Disposable
4.4.1.2 Reusable
4.4.2 BY MATERIAL
4.4.2.1 Glass
4.4.2.2 Plastic
4.4.3 BY PRODUCT
4.4.3.1 Prefilled
4.4.3.2 Fillable
4.5 SELF-INJECTION DEVICES
4.5.1 MARKET SEGMENTATION
4.5.2 SELECTION CRITERIA FOR SELF-INJECTION DEVICE
4.5.3 PEN INJECTORS
4.5.3.1 By Product
4.5.3.1.1 Single chamber pen injectors
4.5.3.1.2 Dual chamber pen injectors
4.5.3.2 By Usability
4.5.3.2.1 Disposable pen injectors
4.5.3.2.2 Reusable pen injectors
4.5.3.3 By Design
4.5.3.3.1 Standard pen injectors
4.5.3.3.2 Customized pen injectors
4.5.4 NEEDLE-FREE INJECTORS
4.5.4.1 By Product
4.5.4.1.1 Prefilled needle free injectors
4.5.4.1.2 Fillable needle free injectors
4.5.4.2 By Technology
4.5.4.2.1 Jet-based needle-free injectors
4.5.4.2.2 Spring-based needle-Free injectors
4.5.4.2.3 Laser-based needle free injectors
4.5.4.2.4 Vibration-based needle free injectors
4.5.4.3 By Usability
4.5.4.3.1 Disposable
4.5.4.3.2 Reusable
4.5.5 AUTO INJECTORS
4.5.5.1 By Product
4.5.5.1.1 Prefilled auto injectors
4.5.5.1.2 Fillable auto injectors
4.5.5.2 By Technology
4.5.5.2.1 Automated auto injectors
4.5.5.2.2 Manual auto injectors
4.5.5.3 By Design
4.5.5.3.1 Standardized auto injectors
4.5.5.3.2 Customized auto injectors
4.5.5.4 By Usability
4.5.5.4.1 Disposable auto injectors
4.5.5.4.2 Reusable auto injectors
4.6 OTHERS
5 INJECTABLE DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET
5.1 INTRODUCTION
5.2 CONVENTIONAL DRUG DELIVERY
5.2.1 INJECTABLE SOLUTIONS
5.2.2 RECONSTITUTED/LYOPHILIZED FORMULATIONS
5.3 NOVEL DRUG DELIVERY FORMULATION TECHNOLOGIES
5.3.1 MARKET SEGMENTATION
5.3.2 LIPOSOMAL SYSTEMS
5.3.3 MICROSPHERES
5.3.4 NANOPARTICLES
5.3.5 POLYMERIC MICELLES
5.3.6 OTHERS
6 INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATIONS
6.1 INTRODUCTION
6.2 AUTO-IMMUNE DISEASES
6.2.1 MULTIPLE SCLEROSIS
6.2.2 RHEUMATOID ARTHRITIS
6.2.3 CROHN'S DISEASE
6.2.4 PSORIASIS
6.2.5 OTHERS
6.3 HORMONAL DISORDERS
6.3.1 DIABETES
6.3.2 ANEMIA
6.3.3 REPRODUCTIVE HEALTH DISEASES
6.3.4 ANTITHROMBOTIC/THROMBOLYTIC THERAPY
6.3.5 OSTEOPOROSIS
6.3.6 GROWTH HORMONE DEFICIENCY
6.4 ORPHAN/RARE DISEASES
6.5 ONCOLOGY
6.6 OTHERS
6.6.1 PAIN MANAGEMENT
6.6.2 HEPATITIS C
6.6.3 ALLERGIES
6.6.4 AESTHETIC TREATMENT
7 GEOGRAPHIC ANALYSIS
7.1 INTRODUCTION
7.1.1 U.S.
7.1.1.1 Product innovation stimulating the growth of injectable drug delivery devices in U.S.
7.1.1.2 Incessant rise in number of diseases requiring injectable drug delivery-based treatment in U.S.
7.1.2 CANADA
7.1.2.1 Rise in number of approvals of injectable drug delivery devices
7.1.2.2 Canadian market impacted due to shortage of injectable drugs
7.1.2.3 Insurance coverage favoring the growth of Canadian injectable drug delivery technology market
8 COMPETITIVE LANDSCAPE
8.1 INTRODUCTION
8.2 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS &
JOINT VENTURES
8.3 NEW PRODUCT LAUNCH
8.4 EXPANSION
8.5 MERGERS & ACQUISITIONS
8.6 OTHER DEVELOPMENTS
8.7 APPROVALS
9 COMPANY PROFILES
(Overview, Financials, Products & Services, Strategy, & Developments)*
9.1 ANTARES PHARMA, INC.
9.2 BAXTER INTERNATIONAL, INC.
9.3 BECTON, DICKINSON AND COMPANY
9.4 ELI LILLY AND COMPANY
9.5 HOSPIRA, INC.
9.6 NOVO NORDISK A/S
9.7 SANOFI
9.8 UNILIFE CORPORATION
9.9 WEST PHARMACEUTICAL SERVICES, INC.
9.10 ZOGENIX, INC.
*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.
1.1 KEY TAKE-AWAYS
1.2 REPORT DESCRIPTION
1.3 MARKETS COVERED
1.4 STAKEHOLDERS
1.5 RESEARCH METHODOLOGY
1.5.1 MARKET SIZE
1.5.2 MARKET SHARE
1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES
1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES
1.5.5 ASSUMPTIONS
2 EXECUTIVE SUMMARY
3 MARKET OVERVIEW
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 MARKET DYNAMICS
3.4 DRIVERS
3.4.1 INNOVATIONS IN INJECTABLE DRUG DELIVERY DEVICES
3.4.2 SURGE OF BIOLOGICS
3.4.3 RISING PREVALENCE OF DIABETES IN THE U.S. AND CANADA
3.4.4 IMPROVEMENT IN PATIENT COMPLIANCE
3.4.5 INCESSANT RISE IN PARTNERSHIPS, COLLABORATIONS AND ACQUISITIONS
3.5 RESTRAINTS
3.5.1 PRODUCT RECALLS
3.5.2 STRINGENT REGULATORY SYSTEMS
3.5.3 NEEDLE-STICK INJURIES AND INFECTIONS
3.6 OPPORTUNITIES
3.6.1 DEVELOPMENT OF BIOSIMILARS
3.6.2 ADVANCEMENTS IN NANOTECHNOLOGY
AND OTHERS
3.7 CHALLENGES
3.7.1 SUSTAINABILITY OF PLAYERS IN HIGHLY COMPETITIVE MARKET
3.8 MARKET SHARE ANALYSIS, BY MAJOR PLAYERS
3.8.1 INJECTABLE DRUG DELIVERY DEVICES
4 INJECTABLE DRUG DELIVERY DEVICES TECHNOLOGIES MARKET
4.1 INTRODUCTION
4.2 MARKET SEGMENTATION
4.3 MANUFACTURERS CRITERIA FOR SELECTION OF AN INJECTABLE DEVICE
4.4 CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES
4.4.1 BY USABILITY
4.4.1.1 Disposable
4.4.1.2 Reusable
4.4.2 BY MATERIAL
4.4.2.1 Glass
4.4.2.2 Plastic
4.4.3 BY PRODUCT
4.4.3.1 Prefilled
4.4.3.2 Fillable
4.5 SELF-INJECTION DEVICES
4.5.1 MARKET SEGMENTATION
4.5.2 SELECTION CRITERIA FOR SELF-INJECTION DEVICE
4.5.3 PEN INJECTORS
4.5.3.1 By Product
4.5.3.1.1 Single chamber pen injectors
4.5.3.1.2 Dual chamber pen injectors
4.5.3.2 By Usability
4.5.3.2.1 Disposable pen injectors
4.5.3.2.2 Reusable pen injectors
4.5.3.3 By Design
4.5.3.3.1 Standard pen injectors
4.5.3.3.2 Customized pen injectors
4.5.4 NEEDLE-FREE INJECTORS
4.5.4.1 By Product
4.5.4.1.1 Prefilled needle free injectors
4.5.4.1.2 Fillable needle free injectors
4.5.4.2 By Technology
4.5.4.2.1 Jet-based needle-free injectors
4.5.4.2.2 Spring-based needle-Free injectors
4.5.4.2.3 Laser-based needle free injectors
4.5.4.2.4 Vibration-based needle free injectors
4.5.4.3 By Usability
4.5.4.3.1 Disposable
4.5.4.3.2 Reusable
4.5.5 AUTO INJECTORS
4.5.5.1 By Product
4.5.5.1.1 Prefilled auto injectors
4.5.5.1.2 Fillable auto injectors
4.5.5.2 By Technology
4.5.5.2.1 Automated auto injectors
4.5.5.2.2 Manual auto injectors
4.5.5.3 By Design
4.5.5.3.1 Standardized auto injectors
4.5.5.3.2 Customized auto injectors
4.5.5.4 By Usability
4.5.5.4.1 Disposable auto injectors
4.5.5.4.2 Reusable auto injectors
4.6 OTHERS
5 INJECTABLE DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET
5.1 INTRODUCTION
5.2 CONVENTIONAL DRUG DELIVERY
5.2.1 INJECTABLE SOLUTIONS
5.2.2 RECONSTITUTED/LYOPHILIZED FORMULATIONS
5.3 NOVEL DRUG DELIVERY FORMULATION TECHNOLOGIES
5.3.1 MARKET SEGMENTATION
5.3.2 LIPOSOMAL SYSTEMS
5.3.3 MICROSPHERES
5.3.4 NANOPARTICLES
5.3.5 POLYMERIC MICELLES
5.3.6 OTHERS
6 INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATIONS
6.1 INTRODUCTION
6.2 AUTO-IMMUNE DISEASES
6.2.1 MULTIPLE SCLEROSIS
6.2.2 RHEUMATOID ARTHRITIS
6.2.3 CROHN'S DISEASE
6.2.4 PSORIASIS
6.2.5 OTHERS
6.3 HORMONAL DISORDERS
6.3.1 DIABETES
6.3.2 ANEMIA
6.3.3 REPRODUCTIVE HEALTH DISEASES
6.3.4 ANTITHROMBOTIC/THROMBOLYTIC THERAPY
6.3.5 OSTEOPOROSIS
6.3.6 GROWTH HORMONE DEFICIENCY
6.4 ORPHAN/RARE DISEASES
6.5 ONCOLOGY
6.6 OTHERS
6.6.1 PAIN MANAGEMENT
6.6.2 HEPATITIS C
6.6.3 ALLERGIES
6.6.4 AESTHETIC TREATMENT
7 GEOGRAPHIC ANALYSIS
7.1 INTRODUCTION
7.1.1 U.S.
7.1.1.1 Product innovation stimulating the growth of injectable drug delivery devices in U.S.
7.1.1.2 Incessant rise in number of diseases requiring injectable drug delivery-based treatment in U.S.
7.1.2 CANADA
7.1.2.1 Rise in number of approvals of injectable drug delivery devices
7.1.2.2 Canadian market impacted due to shortage of injectable drugs
7.1.2.3 Insurance coverage favoring the growth of Canadian injectable drug delivery technology market
8 COMPETITIVE LANDSCAPE
8.1 INTRODUCTION
8.2 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS &
JOINT VENTURES
8.3 NEW PRODUCT LAUNCH
8.4 EXPANSION
8.5 MERGERS & ACQUISITIONS
8.6 OTHER DEVELOPMENTS
8.7 APPROVALS
9 COMPANY PROFILES
(Overview, Financials, Products & Services, Strategy, & Developments)*
9.1 ANTARES PHARMA, INC.
9.2 BAXTER INTERNATIONAL, INC.
9.3 BECTON, DICKINSON AND COMPANY
9.4 ELI LILLY AND COMPANY
9.5 HOSPIRA, INC.
9.6 NOVO NORDISK A/S
9.7 SANOFI
9.8 UNILIFE CORPORATION
9.9 WEST PHARMACEUTICAL SERVICES, INC.
9.10 ZOGENIX, INC.
*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.
LIST OF TABLES
TABLE 1 NORTH AMERICA: INJECTION DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT, 2010 – 2017 ($MILLION)
TABLE 2 NORTH AMERICA: INJECTION DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT, 2010 – 2017 ($MILLION)
TABLE 3 NORTH AMERICA: INJECTION DRUG DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 4 NORTH AMERICA: INJECTABLE DRUG DELIVERY DEVICES TECHNOLOGIES MARKET, BY PRODUCT, 2010 – 2017 ($MILLION)
TABLE 5 NORTH AMERICA: INJECTABLE DRUG DELIVERY DEVICES TECHNOLOGIES MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 6 NORTH AMERICA: CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 7 NORTH AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2010 – 2017 ($MILLION)
TABLE 8 DISPOSABLE CONVENTIONAL DEVICES MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 9 REUSABLE CONVENTIONAL DEVICES MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 10 NORTH AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2010 – 2017 ($MILLION)
TABLE 11 CONVENTIONAL INJECTION DEVICES (GLASS) MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 12 CONVENTIONAL INJECTION DEVICES (PLASTIC) MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 13 NORTH AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2010 – 2017 ($MILLION)
TABLE 14 NORTH AMERICA: PREFILLED CONVENTIONAL INJECTION DEVICES MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 15 NORTH AMERICA: FILLABLE CONVENTIONAL INJECTION DEVICES MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 16 NORTH AMERICA: SELF-INJECTION DEVICES MARKET, BY PRODUCT, 2010 – 2017 ($MILLION)
TABLE 17 NORTH AMERICA: SELF-INJECTION DEVICES MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 18 NORTH AMERICA: PEN INJECTOR MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 19 NORTH AMERICA: PEN INJECTORS MARKET, BY PRODUCT, 2010 – 2017 ($MILLION)
TABLE 20 NORTH AMERICA: SINGLE CHAMBER PEN INJECTOR MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 21 NORTH AMERICA: DUAL CHAMBER PEN INJECTOR MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 22 NORTH AMERICA: PEN INJECTORS MARKET, BY USABILITY, 2010 – 2017 ($MILLION)
TABLE 23 NORTH AMERICA: DISPOSABLE PEN INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 24 NORTH AMERICA: REUSABLE PEN INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 25 NORTH AMERICA: PEN INJECTORS MARKET, BY DESIGN, 2010 – 2017 ($MILLION)
TABLE 26 NORTH AMERICA: STANDARD PEN INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 27 NORTH AMERICA: CUSTOMIZED PEN INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 28 NORTH AMERICA: NEEDLE FREE INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 29 NORTH AMERICA: NEEDLE FREE INJECTORS MARKET, BY PRODUCT, 2010 – 2017 ($MILLION)
TABLE 30 NORTH AMERICA: PREFILLED NEEDLE FREE INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 31 NORTH AMERICA: FILLABLE NEEDLE FREE INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 32 NORTH AMERICA: NEEDLE FREE INJECTORS MARKET, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 33 NORTH AMERICA: JET-BASED NEEDLE FREE INJECTOR MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 34 NORTH AMERICA: SPRING-BASED NEEDLE FREE INJECTOR MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 35 NORTH AMERICA: LASER-POWERED NEEDLE FREE INJECTOR MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 36 NORTH AMERICA: VIBRATION-BASED NEEDLE FREE INJECTOR MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 37 NORTH AMERICA: NEEDLE FREE INJECTORS MARKET, BY USABILITY, 2010 – 2017 ($MILLION)
TABLE 38 NORTH AMERICA: DISPOSABLE NEEDLE FREE INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 39 NORTH AMERICA: REUSABLE NEEDLE FREE INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 40 NORTH AMERICA: AUTO INJECTORS PRODUCTS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 41 NORTH AMERICA: AUTO INJECTORS MARKET, BY PRODUCT, 2010 – 2017 ($MILLION)
TABLE 42 NORTH AMERICA: PREFILLED AUTO INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 43 NORTH AMERICA: FILLABLE AUTO INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 44 NORTH AMERICA: AUTO INJECTORS MARKET, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 45 NORTH AMERICA: AUTOMATED AUTO INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 46 NORTH AMERICA: MANUAL AUTO INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 47 NORTH AMERICA: AUTO INJECTORS MARKET, BY DESIGN, 2010 – 2017 ($MILLION)
TABLE 48 NORTH AMERICA: STANDARDIZED AUTO INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 49 NORTH AMERICA: CUSTOMIZED AUTO INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 50 NORTH AMERICA: AUTO INJECTORS MARKET, BY USABILITY, 2010 – 2017 ($MILLION)
TABLE 51 NORTH AMERICA: DISPOSABLE AUTO INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 52 NORTH AMERICA: REUSABLE AUTO INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 53 NORTH AMERICA: OTHERS INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 54 NORTH AMERICA: INJECTABLE DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, BY SEGMENT, 2010 – 2017 ($MILLION)
TABLE 55 NORTH AMERICA: INJECTABLE DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 56 NORTH AMERICA: CONVENTIONAL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, 2010 – 2017 ($MILLION)
TABLE 57 NORTH AMERICA: CONVENTIONAL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 58 NORTH AMERICA: INJECTABLE SOLUTIONS CONVENTIONAL DRUG DELIVERY FORMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 59 NORTH AMERICA: RECONSTITUTED/LYOPHILIZED CONVENTIONAL DRUG DELIVERY FORMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 60 NORTH AMERICA: NOVEL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, 2010 – 2017 ($MILLION)
TABLE 61 NORTH AMERICA: NOVEL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 62 NORTH AMERICA: LIPOSOME DRUG DELIVERY FORMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 63 NORTH AMERICA: MICROSPHERES DRUG DELIVERY FORMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 64 NORTH AMERICA: NANOPARTICLES DRUG DELIVERY FORMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 65 NORTH AMERICA: POLYMERIC MICELLES DRUG DELIVERY FORMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 66 NORTH AMERICA: OTHERS NOVEL DRUG DELIVERY FORMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 67 NORTH AMERICAN INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATIONS, 2010 – 2017 ($MILLION)
TABLE 68 NORTH AMERICA: AUTO IMMUNE THERAPEUTICS MARKET, BY INDICATION, 2010 – 2017 ($MILLION)
TABLE 69 NORTH AMERICA: AUTO IMMUNE THERAPEUTICS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 70 NORTH AMERICA: MULTIPLE SCLEROSIS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 71 NORTH AMERICA: RHEUMATOID ARTHRITIS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 72 NORTH AMERICA: CROHN'S DISEASE MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 73 PSORIASIS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 74 NORTH AMERICA: OTHER AUTO IMMUNE DISEASE MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 75 NORTH AMERICA: HORMONAL DISORDERS MARKET, BY INDICATION, 2010 – 2017 ($MILLION)
TABLE 76 NORTH AMERICA: HORMONAL DISORDERS MARKET, BY COUNTRY, 2010 – 2017($MILLION)
TABLE 77 NORTH AMERICA: DIABETES MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 78 NORTH AMERICA: ANEMIA MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 79 NORTH AMERICA: REPRODUCTIVE HEALTH DISEASE MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 80 NORTH AMERICA: ANTITHROMBOTIC THERAPY MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 81 NORTH AMERICA: OSTEOPOROSIS MARKET, BY COUNTRY, 2010 – 2017($MILLION)
TABLE 82 NORTH AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 83 NORTH AMERICA: ORPHAN/RARE DISEASE MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 84 NORTH AMERICA: ONCOLOGY MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 85 NORTH AMERICA: OTHER THERAPEUTIC MARKET, BY INDICATION, 2010 – 2017 ($MILLION)
TABLE 86 NORTH AMERICA: OTHER THERAPEUTIC MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 87 NORTH AMERICA: PAIN MANAGEMENT MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 88 NORTH AMERICA: HEPATITIS C MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 89 NORTH AMERICA: ALLERGIES/ANAPHYLYTIC SHOCK MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 90 NORTH AMERICA: AESTHETIC TREATMENT MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 91 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 92 UNITED STATES: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT, 2010 – 2017 ($MILLION)
TABLE 93 UNITED STATES: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY PRODUCT, 2010 – 2017 ($MILLION)
TABLE 94 UNITED STATES: INJECTABLE DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, BY PRODUCT, 2010 – 2017($MILLION)
TABLE 95 UNITED STATES: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATION, 2010 – 2017 ($MILLION)
TABLE 96 CANADA: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2010 – 2017 ($MILLION)
TABLE 97 CANADA: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY PRODUCT, 2010 – 2017 ($MILLION)
TABLE 98 CANADA: INJECTABLE DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, BY SEGMENT, 2010 – 2017 ($MILLION)
TABLE 99 CANADA: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATION, 2010 – 2017 ($MILLION)
TABLE 100 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES, 2010 – 2013
TABLE 101 NEW PRODUCT LAUNCH, 2010 – 2013
TABLE 102 EXPANSION, 2010 – 2012
TABLE 103 MERGERS & ACQUISITIONS, 2010 – 2013
TABLE 104 OTHERS, 2010 – 2013
TABLE 105 APPROVALS, 2010 – 2013
TABLE 106 ANTARES PHARMA: TOTAL REVENUES AND R&D EXPENDITURE, 2010 – 2012 ($MILLION)
TABLE 107 ANTARES PHARMA: TOTAL REVENUE, BY PRODUCT, 2010 – 2012 ($MILLION)
TABLE 108 ANTARES PHARMA: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($MILLION)
TABLE 109 BAXTER INTERNATIONAL: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($MILLION)
TABLE 110 BAXTER INTERNATIONAL: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION)
TABLE 111 BAXTER INTERNATIONAL: MEDICAL PRODUCTS TOTAL REVENUE, 2010 – 2012($MILLION)
TABLE 112 BAXTER INTERNATIONAL: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($MILLION)
TABLE 113 BECTON DICKINSON: TOTAL REVENUE AND R&D EXPENDITURE, 2010 – 2012 ($MILLION)
TABLE 114 BECTON DICKINSON: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION)
TABLE 115 BECTON DICKINSON: MEDICAL DIVISION TOTAL REVENUE, 2010 – 2012 ($MILLION)
TABLE 116 BECTON DICKINSON: TOTAL REVENUE, BY GEOGRAPHY, 2010– 2012 ($MILLION)
TABLE 117 ELI LILLY & CO: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($BILLION)
TABLE 118 ELI LILLY & CO: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($BILLION)
TABLE 119 ELI LILLY & CO: TOTAL REVENUE BY GEOGRAPHY, 2010 – 2012 ($BILLION)
TABLE 120 HOSPIRA, INC.: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011 ($MILLION)
TABLE 121 HOSPIRA, INC.: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)
TABLE 122 HOSPIRA, INC.: TOTAL REVENUE, BY SEGMENT, 2009 – 2011($MILLION)
TABLE 123 NOVO NORDISK: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($BILLION)
TABLE 124 NOVO NORDISK: TOTAL REVENUE, BY SEGMENT, 2010 – 2012($BILLION)
TABLE 125 NOVO NORDISK: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($BILLION)
TABLE 126 SANOFI: TOTAL REVENUE & R&D EXPENDITURE, 2009 – 2012 ($BILLION)
TABLE 127 SANOFI: TOTAL REVENUE, BY SEGMENT, 2009 – 2012 ($BILLION)
TABLE 128 SANOFI: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2012 ($BILLION)
TABLE 129 UNILIFE CORPORATION: TOTAL REVENUE AND EXPENDITURE, 2009 – 2011 ($MILLION)
TABLE 130 UNILIFE CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)
TABLE 131 WEST PHARMA: TOTAL REVENUES AND R&D EXPENSES, 2009 – 2012 ($MILLION)
TABLE 132 WEST PHARMA: TOTAL REVENUE, BY SEGMENT, 2009 – 2012 ($MILLION)
TABLE 133 WEST PHARMA: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2012 ($MILLION)
TABLE 134 ZOGENIX, INC.: TOTAL REVENUE AND R&D EXPENDITURE, 2010 – 2012 ($MILLION)
TABLE 1 NORTH AMERICA: INJECTION DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT, 2010 – 2017 ($MILLION)
TABLE 2 NORTH AMERICA: INJECTION DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT, 2010 – 2017 ($MILLION)
TABLE 3 NORTH AMERICA: INJECTION DRUG DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 4 NORTH AMERICA: INJECTABLE DRUG DELIVERY DEVICES TECHNOLOGIES MARKET, BY PRODUCT, 2010 – 2017 ($MILLION)
TABLE 5 NORTH AMERICA: INJECTABLE DRUG DELIVERY DEVICES TECHNOLOGIES MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 6 NORTH AMERICA: CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 7 NORTH AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2010 – 2017 ($MILLION)
TABLE 8 DISPOSABLE CONVENTIONAL DEVICES MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 9 REUSABLE CONVENTIONAL DEVICES MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 10 NORTH AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2010 – 2017 ($MILLION)
TABLE 11 CONVENTIONAL INJECTION DEVICES (GLASS) MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 12 CONVENTIONAL INJECTION DEVICES (PLASTIC) MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 13 NORTH AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2010 – 2017 ($MILLION)
TABLE 14 NORTH AMERICA: PREFILLED CONVENTIONAL INJECTION DEVICES MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 15 NORTH AMERICA: FILLABLE CONVENTIONAL INJECTION DEVICES MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 16 NORTH AMERICA: SELF-INJECTION DEVICES MARKET, BY PRODUCT, 2010 – 2017 ($MILLION)
TABLE 17 NORTH AMERICA: SELF-INJECTION DEVICES MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 18 NORTH AMERICA: PEN INJECTOR MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 19 NORTH AMERICA: PEN INJECTORS MARKET, BY PRODUCT, 2010 – 2017 ($MILLION)
TABLE 20 NORTH AMERICA: SINGLE CHAMBER PEN INJECTOR MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 21 NORTH AMERICA: DUAL CHAMBER PEN INJECTOR MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 22 NORTH AMERICA: PEN INJECTORS MARKET, BY USABILITY, 2010 – 2017 ($MILLION)
TABLE 23 NORTH AMERICA: DISPOSABLE PEN INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 24 NORTH AMERICA: REUSABLE PEN INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 25 NORTH AMERICA: PEN INJECTORS MARKET, BY DESIGN, 2010 – 2017 ($MILLION)
TABLE 26 NORTH AMERICA: STANDARD PEN INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 27 NORTH AMERICA: CUSTOMIZED PEN INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 28 NORTH AMERICA: NEEDLE FREE INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 29 NORTH AMERICA: NEEDLE FREE INJECTORS MARKET, BY PRODUCT, 2010 – 2017 ($MILLION)
TABLE 30 NORTH AMERICA: PREFILLED NEEDLE FREE INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 31 NORTH AMERICA: FILLABLE NEEDLE FREE INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 32 NORTH AMERICA: NEEDLE FREE INJECTORS MARKET, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 33 NORTH AMERICA: JET-BASED NEEDLE FREE INJECTOR MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 34 NORTH AMERICA: SPRING-BASED NEEDLE FREE INJECTOR MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 35 NORTH AMERICA: LASER-POWERED NEEDLE FREE INJECTOR MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 36 NORTH AMERICA: VIBRATION-BASED NEEDLE FREE INJECTOR MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 37 NORTH AMERICA: NEEDLE FREE INJECTORS MARKET, BY USABILITY, 2010 – 2017 ($MILLION)
TABLE 38 NORTH AMERICA: DISPOSABLE NEEDLE FREE INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 39 NORTH AMERICA: REUSABLE NEEDLE FREE INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 40 NORTH AMERICA: AUTO INJECTORS PRODUCTS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 41 NORTH AMERICA: AUTO INJECTORS MARKET, BY PRODUCT, 2010 – 2017 ($MILLION)
TABLE 42 NORTH AMERICA: PREFILLED AUTO INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 43 NORTH AMERICA: FILLABLE AUTO INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 44 NORTH AMERICA: AUTO INJECTORS MARKET, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 45 NORTH AMERICA: AUTOMATED AUTO INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 46 NORTH AMERICA: MANUAL AUTO INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 47 NORTH AMERICA: AUTO INJECTORS MARKET, BY DESIGN, 2010 – 2017 ($MILLION)
TABLE 48 NORTH AMERICA: STANDARDIZED AUTO INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 49 NORTH AMERICA: CUSTOMIZED AUTO INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 50 NORTH AMERICA: AUTO INJECTORS MARKET, BY USABILITY, 2010 – 2017 ($MILLION)
TABLE 51 NORTH AMERICA: DISPOSABLE AUTO INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 52 NORTH AMERICA: REUSABLE AUTO INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 53 NORTH AMERICA: OTHERS INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 54 NORTH AMERICA: INJECTABLE DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, BY SEGMENT, 2010 – 2017 ($MILLION)
TABLE 55 NORTH AMERICA: INJECTABLE DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 56 NORTH AMERICA: CONVENTIONAL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, 2010 – 2017 ($MILLION)
TABLE 57 NORTH AMERICA: CONVENTIONAL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 58 NORTH AMERICA: INJECTABLE SOLUTIONS CONVENTIONAL DRUG DELIVERY FORMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 59 NORTH AMERICA: RECONSTITUTED/LYOPHILIZED CONVENTIONAL DRUG DELIVERY FORMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 60 NORTH AMERICA: NOVEL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, 2010 – 2017 ($MILLION)
TABLE 61 NORTH AMERICA: NOVEL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 62 NORTH AMERICA: LIPOSOME DRUG DELIVERY FORMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 63 NORTH AMERICA: MICROSPHERES DRUG DELIVERY FORMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 64 NORTH AMERICA: NANOPARTICLES DRUG DELIVERY FORMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 65 NORTH AMERICA: POLYMERIC MICELLES DRUG DELIVERY FORMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 66 NORTH AMERICA: OTHERS NOVEL DRUG DELIVERY FORMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 67 NORTH AMERICAN INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATIONS, 2010 – 2017 ($MILLION)
TABLE 68 NORTH AMERICA: AUTO IMMUNE THERAPEUTICS MARKET, BY INDICATION, 2010 – 2017 ($MILLION)
TABLE 69 NORTH AMERICA: AUTO IMMUNE THERAPEUTICS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 70 NORTH AMERICA: MULTIPLE SCLEROSIS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 71 NORTH AMERICA: RHEUMATOID ARTHRITIS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 72 NORTH AMERICA: CROHN'S DISEASE MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 73 PSORIASIS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 74 NORTH AMERICA: OTHER AUTO IMMUNE DISEASE MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 75 NORTH AMERICA: HORMONAL DISORDERS MARKET, BY INDICATION, 2010 – 2017 ($MILLION)
TABLE 76 NORTH AMERICA: HORMONAL DISORDERS MARKET, BY COUNTRY, 2010 – 2017($MILLION)
TABLE 77 NORTH AMERICA: DIABETES MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 78 NORTH AMERICA: ANEMIA MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 79 NORTH AMERICA: REPRODUCTIVE HEALTH DISEASE MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 80 NORTH AMERICA: ANTITHROMBOTIC THERAPY MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 81 NORTH AMERICA: OSTEOPOROSIS MARKET, BY COUNTRY, 2010 – 2017($MILLION)
TABLE 82 NORTH AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 83 NORTH AMERICA: ORPHAN/RARE DISEASE MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 84 NORTH AMERICA: ONCOLOGY MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 85 NORTH AMERICA: OTHER THERAPEUTIC MARKET, BY INDICATION, 2010 – 2017 ($MILLION)
TABLE 86 NORTH AMERICA: OTHER THERAPEUTIC MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 87 NORTH AMERICA: PAIN MANAGEMENT MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 88 NORTH AMERICA: HEPATITIS C MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 89 NORTH AMERICA: ALLERGIES/ANAPHYLYTIC SHOCK MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 90 NORTH AMERICA: AESTHETIC TREATMENT MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 91 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 92 UNITED STATES: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT, 2010 – 2017 ($MILLION)
TABLE 93 UNITED STATES: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY PRODUCT, 2010 – 2017 ($MILLION)
TABLE 94 UNITED STATES: INJECTABLE DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, BY PRODUCT, 2010 – 2017($MILLION)
TABLE 95 UNITED STATES: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATION, 2010 – 2017 ($MILLION)
TABLE 96 CANADA: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2010 – 2017 ($MILLION)
TABLE 97 CANADA: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY PRODUCT, 2010 – 2017 ($MILLION)
TABLE 98 CANADA: INJECTABLE DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, BY SEGMENT, 2010 – 2017 ($MILLION)
TABLE 99 CANADA: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATION, 2010 – 2017 ($MILLION)
TABLE 100 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES, 2010 – 2013
TABLE 101 NEW PRODUCT LAUNCH, 2010 – 2013
TABLE 102 EXPANSION, 2010 – 2012
TABLE 103 MERGERS & ACQUISITIONS, 2010 – 2013
TABLE 104 OTHERS, 2010 – 2013
TABLE 105 APPROVALS, 2010 – 2013
TABLE 106 ANTARES PHARMA: TOTAL REVENUES AND R&D EXPENDITURE, 2010 – 2012 ($MILLION)
TABLE 107 ANTARES PHARMA: TOTAL REVENUE, BY PRODUCT, 2010 – 2012 ($MILLION)
TABLE 108 ANTARES PHARMA: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($MILLION)
TABLE 109 BAXTER INTERNATIONAL: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($MILLION)
TABLE 110 BAXTER INTERNATIONAL: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION)
TABLE 111 BAXTER INTERNATIONAL: MEDICAL PRODUCTS TOTAL REVENUE, 2010 – 2012($MILLION)
TABLE 112 BAXTER INTERNATIONAL: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($MILLION)
TABLE 113 BECTON DICKINSON: TOTAL REVENUE AND R&D EXPENDITURE, 2010 – 2012 ($MILLION)
TABLE 114 BECTON DICKINSON: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION)
TABLE 115 BECTON DICKINSON: MEDICAL DIVISION TOTAL REVENUE, 2010 – 2012 ($MILLION)
TABLE 116 BECTON DICKINSON: TOTAL REVENUE, BY GEOGRAPHY, 2010– 2012 ($MILLION)
TABLE 117 ELI LILLY & CO: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($BILLION)
TABLE 118 ELI LILLY & CO: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($BILLION)
TABLE 119 ELI LILLY & CO: TOTAL REVENUE BY GEOGRAPHY, 2010 – 2012 ($BILLION)
TABLE 120 HOSPIRA, INC.: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011 ($MILLION)
TABLE 121 HOSPIRA, INC.: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)
TABLE 122 HOSPIRA, INC.: TOTAL REVENUE, BY SEGMENT, 2009 – 2011($MILLION)
TABLE 123 NOVO NORDISK: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($BILLION)
TABLE 124 NOVO NORDISK: TOTAL REVENUE, BY SEGMENT, 2010 – 2012($BILLION)
TABLE 125 NOVO NORDISK: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($BILLION)
TABLE 126 SANOFI: TOTAL REVENUE & R&D EXPENDITURE, 2009 – 2012 ($BILLION)
TABLE 127 SANOFI: TOTAL REVENUE, BY SEGMENT, 2009 – 2012 ($BILLION)
TABLE 128 SANOFI: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2012 ($BILLION)
TABLE 129 UNILIFE CORPORATION: TOTAL REVENUE AND EXPENDITURE, 2009 – 2011 ($MILLION)
TABLE 130 UNILIFE CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)
TABLE 131 WEST PHARMA: TOTAL REVENUES AND R&D EXPENSES, 2009 – 2012 ($MILLION)
TABLE 132 WEST PHARMA: TOTAL REVENUE, BY SEGMENT, 2009 – 2012 ($MILLION)
TABLE 133 WEST PHARMA: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2012 ($MILLION)
TABLE 134 ZOGENIX, INC.: TOTAL REVENUE AND R&D EXPENDITURE, 2010 – 2012 ($MILLION)
LIST OF FIGURES
FIGURE 1 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET
FIGURE 2 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY COUNTRY
FIGURE 3 INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET SEGMENTATION
FIGURE 4 MARKET SEGMENTATION OF INJECTABLE DRUG DELIVERY TECHNOLOGIES
FIGURE 5 MARKET SEGMENTATION OF INJECTABLE DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATION
FIGURE 6 INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET DYNAMICS
FIGURE 7 NORTH AMERICA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY KEY PLAYERS, 2012
FIGURE 8 INJECTABLE DRUG DELIVERY DEVICES TECHNOLOGIES MARKET SEGMENTATION
FIGURE 9 FACTORS AFFECTING SELECTION OF AN INJECTABLE DEVICE
FIGURE 10 NORTH AMERICA: SELF-INJECTION DEVICES MARKET, BY PRODUCT, 2010 & 2017 ($MILLION)
FIGURE 11 SELF-INJECTION DEVICES MARKET SEGMENTATION
FIGURE 12 FACTORS AFFECTING SELECTION OF SELF-INJECTION DEVICE
FIGURE 13 NORTH AMERICA: CONVENTIONAL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET SEGMENTATION
FIGURE 14 NORTH AMERICA: CONVENTIONAL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, 2012 & 2017
FIGURE 15 NORTH AMERICA: NOVEL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET
FIGURE 16 NORTH AMERICA: NOVEL DRUG DELIVERY FORMULATION TECHNOLOGIES SEGMENTATION
FIGURE 17 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATIONS, 2010 – 2017 ($MILLION)
FIGURE 18 INJECTABLE DRUG DELIVERY THERAPEUTICS MARKET SEGMENTATION
FIGURE 19 AUTO-IMMUNE THERAPEUTICS MARKET SEGMENTATION
FIGURE 20 HORMONAL DISORDERS MARKET SEGMENTATION
FIGURE 21 KEY GROWTH STRATEGIES, 2010 – 2013
FIGURE 22 KEY PLAYERS FOCUSING ON AGREEMENTS, PARTNERSHIPS, COLLABORATIONS AND JOINT VENTURES STRATEGY, 2010 – 2013
FIGURE 23 KEY PLAYERS FOCUSING ON NEW PRODUCT LAUNCH STRATEGY, 2010 – 2013
FIGURE 24 KEY PLAYERS FOCUSING ON EXPANSION, 2010 – 2013
FIGURE 1 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET
FIGURE 2 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY COUNTRY
FIGURE 3 INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET SEGMENTATION
FIGURE 4 MARKET SEGMENTATION OF INJECTABLE DRUG DELIVERY TECHNOLOGIES
FIGURE 5 MARKET SEGMENTATION OF INJECTABLE DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATION
FIGURE 6 INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET DYNAMICS
FIGURE 7 NORTH AMERICA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY KEY PLAYERS, 2012
FIGURE 8 INJECTABLE DRUG DELIVERY DEVICES TECHNOLOGIES MARKET SEGMENTATION
FIGURE 9 FACTORS AFFECTING SELECTION OF AN INJECTABLE DEVICE
FIGURE 10 NORTH AMERICA: SELF-INJECTION DEVICES MARKET, BY PRODUCT, 2010 & 2017 ($MILLION)
FIGURE 11 SELF-INJECTION DEVICES MARKET SEGMENTATION
FIGURE 12 FACTORS AFFECTING SELECTION OF SELF-INJECTION DEVICE
FIGURE 13 NORTH AMERICA: CONVENTIONAL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET SEGMENTATION
FIGURE 14 NORTH AMERICA: CONVENTIONAL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, 2012 & 2017
FIGURE 15 NORTH AMERICA: NOVEL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET
FIGURE 16 NORTH AMERICA: NOVEL DRUG DELIVERY FORMULATION TECHNOLOGIES SEGMENTATION
FIGURE 17 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATIONS, 2010 – 2017 ($MILLION)
FIGURE 18 INJECTABLE DRUG DELIVERY THERAPEUTICS MARKET SEGMENTATION
FIGURE 19 AUTO-IMMUNE THERAPEUTICS MARKET SEGMENTATION
FIGURE 20 HORMONAL DISORDERS MARKET SEGMENTATION
FIGURE 21 KEY GROWTH STRATEGIES, 2010 – 2013
FIGURE 22 KEY PLAYERS FOCUSING ON AGREEMENTS, PARTNERSHIPS, COLLABORATIONS AND JOINT VENTURES STRATEGY, 2010 – 2013
FIGURE 23 KEY PLAYERS FOCUSING ON NEW PRODUCT LAUNCH STRATEGY, 2010 – 2013
FIGURE 24 KEY PLAYERS FOCUSING ON EXPANSION, 2010 – 2013
